Warfarin label change advises on genetic factors

Share this article:
The FDA rang in the era of personalized medicine with a labeling change on blood thinner warfarin cautioning that patients with either of two genetic variations might respond differently to the drug, which is sold by Bristol-Myers Squibb under the Coumadin brand.
The label change marks the first time FDA has employed gene-specific information in a label for a major drug, said Dr. Larry Lesko, director of the office of clinical pharmacology at CDER. “This means personalized medicine is no longer an abstract concept but has moved into the mainstream, where it is recommended as a factor in a drug used by millions of people every day,” said Lesko in a press call.
The agency cited the change as evidence of progress in its Critical Path Initiative, whereby FDA hopes to hasten the advent of personalized medicine through encouraging the use of biomarkers in diagnosis, treatment and drug development.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?